Company profile EDIT
Editas Medicine Inc
unlocking the promise of genome editing to deliver life-changing medicines. editas medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.Company either doesn't exist or there are no keywords for EDIT Google Trends
Useful links and data for EDIT
Earnings date: 2024-02-22 After close
Company name: Editas Medicine Inc
Sector: Manufacturing
Company's websiteHyperchartsYahoo FinanceMarketWatchStockTwitsSEC FilingsSwaggyStocksLatest articles
2026-10-14T06:00:00-07:00
GlobeNewswire
Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference2026-10-08T15:25:59.622553105Z
Analyst Upgrades
Wells Fargo Upgrades Editas Medicine to Overweight, Raises Price Target to $62026-10-08T04:00:00-07:00
GlobeNewswire
Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia2026-09-23T12:29:58.594279403Z
Analyst Upgrades
Guggenheim Upgrades Editas Medicine to Buy, Announces $5 Price Target2026-09-09T06:00:00-07:00
GlobeNewswire
Editas Medicine Reports Inducement Grants to New Chief Medical Officer2026-09-08T04:00:00-07:00
GlobeNewswire
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer2026-09-01T06:00:00-07:00
GlobeNewswire
Editas Medicine to Participate in Upcoming Investor Conferences2026-08-05T13:01:00-07:00
GlobeNewswire
Editas Medicine Announces Second Quarter 2026 Results and Business Updates2026-08-04T13:15:00-07:00
GlobeNewswire
Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.2026-05-28T20:01:00Z
GlobeNewswire
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference2026-05-26T13:05:00Z
GlobeNewswire
Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering2026-05-26T10:15:03Z
GlobeNewswire
Editas Medicine Announces Proposed Public Offering2026-05-26T10:01:00Z
GlobeNewswire
Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress2026-05-14T10:01:00Z
GlobeNewswire
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting2026-05-05T20:51:33Z
Analyst Upgrades
Chardan Capital Maintains Buy on Editas Medicine, Raises Price Target to $4